RECRUITING

Beta-Blocker Influences on Inflammatory and Neural Responses to Stress

Conditions

Cardiovascular Disease Beta-Blockade Inflammation Neuroimaging

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to map the neural and molecular mechanisms underlying psychological stress-induced changes in inflammation which could reveal new targets for intervention to reduce the risk of cardiovascular disease.

Official Title

Beta-Blocker Influences on Inflammatory and Neural Responses to Stress

Quick Facts

Study Start:2024-05-01

Study Completion:2026-05

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06263452

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 30 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Yes

Standard Ages:ADULT

Inclusion Criteria	Exclusion Criteria
* Ages 18-30 years * Right-handed * Fluent in English reading, writing, and speaking at least at a 10th grade level * Body mass index (BMI) less than or equal to 35 kg/m\^2	* Non-removeable metal devices/implants/objects in the body * Severe claustrophobia (assessed by self-report) * Currently pregnant * Left-handed * Body mass index (BMI) greater than 35 kg/m\^2 * History of fainting spells or any heart condition * History of or present low resting heart rate (\< 60 BPM) and/or low blood pressure (systolic blood pressure \< 80mmHg) * Self-reported physical illnesses: diabetes, cardiovascular diseases, high blood pressure, inflammatory bowel diseases, rheumatoid arthritis, asthma, autoimmune disease, Crohn's disease, ulcerative colitis, lupus * Any self-reported diagnosed mental illness * Current use of prescription medications * Current or recent regular nicotine/tobacco use (cigarettes, e-cigarettes, vape, chewing tobacco, nicotine gum) * Current regular (daily or almost daily) recreational drug use = 4 or more times per week * Received any vaccine within the past two weeks * Severe sleep disturbance (3-4 hours of sleep loss) the night before Session II * Vigorous physical activity on the day of Session II * Acute illness or allergy symptoms on the day of Session II * Usage of over-the-counter medications on the day of Session II * Usage of recreational drugs within 48 hours of Session II * Usage of alcohol on the day of Session II

Inclusion Criteria

Exclusion Criteria

* Ages 18-30 years
* Right-handed
* Fluent in English reading, writing, and speaking at least at a 10th grade level
* Body mass index (BMI) less than or equal to 35 kg/m\^2

* Non-removeable metal devices/implants/objects in the body
* Severe claustrophobia (assessed by self-report)
* Currently pregnant
* Left-handed
* Body mass index (BMI) greater than 35 kg/m\^2
* History of fainting spells or any heart condition
* History of or present low resting heart rate (\< 60 BPM) and/or low blood pressure (systolic blood pressure \< 80mmHg)
* Self-reported physical illnesses: diabetes, cardiovascular diseases, high blood pressure, inflammatory bowel diseases, rheumatoid arthritis, asthma, autoimmune disease, Crohn's disease, ulcerative colitis, lupus
* Any self-reported diagnosed mental illness
* Current use of prescription medications
* Current or recent regular nicotine/tobacco use (cigarettes, e-cigarettes, vape, chewing tobacco, nicotine gum)
* Current regular (daily or almost daily) recreational drug use = 4 or more times per week
* Received any vaccine within the past two weeks
* Severe sleep disturbance (3-4 hours of sleep loss) the night before Session II
* Vigorous physical activity on the day of Session II
* Acute illness or allergy symptoms on the day of Session II
* Usage of over-the-counter medications on the day of Session II
* Usage of recreational drugs within 48 hours of Session II
* Usage of alcohol on the day of Session II

Contacts and Locations

Study Contact

Madison K Tarkenton, BA

CONTACT

9197102168

mktark@unc.edu

Keely A Muscatell, PhD

CONTACT

9164957661

kmuscatell@unc.edu

Principal Investigator

Keely Muscatell, PhD

PRINCIPAL_INVESTIGATOR

University of North Carolina, Chapel Hill

Study Locations (Sites)

Social Neuroscience and Health Laboratory

Chapel Hill, North Carolina, 27514

United States

Collaborators and Investigators

Sponsor: University of North Carolina, Chapel Hill

Keely Muscatell, PhD, PRINCIPAL_INVESTIGATOR, University of North Carolina, Chapel Hill

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-05-01

Study Completion Date2026-05

Study Record Updates

Study Start Date2024-05-01

Study Completion Date2026-05

Terms related to this study

Keywords Provided by Researchers

Beta-Blockade
Inflammation
Neuroimaging

Additional Relevant MeSH Terms

Cardiovascular Disease